Risk of acute liver injury associated with the use of drugs: a multicentre population survey

Sabaté, Mònica; Ibáñez, Luisa; Pérez, Elena Cónde; Vidal, Xavier; Buti, María; Xiol, Xavier; Mas, Antoni; Guarner, Carlos; Forné, Montserrat; Solá, Ricard; Castellote, José; Rigau, Joaquim; Laporte, Joan‐Ramon

doi:10.1111/j.1365-2036.2007.03338.x

Cited by 60 publications

(45 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The DLT of acute hepatotoxicity occurred at dose level 150 mg; the patient presented the toxicity at the end of chemotherapy treatment when she was also taking erythromycin and antiemetics. Acute severe hepatitis, though rare, is occasionally observed with EGFR inhibitors gefitinib or erlotinib (33), cisplatin (34), and erythromycin (35). All medications were interrupted and the patient presented complete recovery.…”

Section: Discussionmentioning

confidence: 99%

Phase I Trial of Erlotinib Combined with Cisplatin and Radiotherapy for Patients with Locally Advanced Cervical Squamous Cell Cancer

Nogueira-Rodrigues

Carmo

Viégas

et al. 2008

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: This phase I trial was aimed to determine the maximum tolerated dose and related toxicity of erlotinib (E) when administered concurrently with standard chemoradiation (CRT) for cervical cancer. Experimental Design: In a modified Fibonacci design, the study aimed to study three cohorts of at least three patients receiving escalating doses of erlotinib (50/100/150 mg) combined with cisplatin (40 mg/m 2 , weekly, 5 cycles) and radiotherapy (external beam 4,500 cGy in 25 fractions, followed by 4 fractions/600 cGy/weekly of brachytherapy) in squamous cell cervical carcinoma patients, stage IIB to IIIB. Results: Fifteen patients were enrolled, 3 at dose level (DL) 50 mg, 4 at DL100 mg, and 8 at DL 150 mg. Patients presented median age 47 (36-59), stage IIB (46.2%) and IIIB (53.8%). Overall, E+CRT was well-tolerated. Three patients did not complete the planned schedule. One patient at DL 100 mg withdrew informed consent due to grade 2 rash; at DL 150 mg, 1 patient presented Raynaud's Syndrome and had C interrupted, and another patient presented grade 4 hepatotoxicity. The latter was interpreted as dose limiting toxicity and a new cohort of 150 mg was started. No further grade 4 toxicity occurred. Grade 3 toxicity occurred in 6 cases: diarrhea in 3 patients, rash in 2 patients, and leukopenia in 1 patient. E+CRT did not lead to limiting in-field toxicity. Conclusions: E+CRT is feasible to locally advanced squamous cell cervical cancer and is well tolerated.The maximum tolerated dose has been defined as150 mg.To the best of our knowledge, this is the first report of a combination of erlotinib, cisplatin, and pelvic radiotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Phase I Trial of Erlotinib Combined with Cisplatin and Radiotherapy for Patients with Locally Advanced Cervical Squamous Cell Cancer

Nogueira-Rodrigues

Carmo

Viégas

et al. 2008

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…The possibility that omeprazole and/or amoxycillin had caused or contributed to liver injury cannot be excluded as they had been previously reported to cause acute liver injury [7,8]. However, proton pump inhibitors were not identified as hepatotoxic in a large ongoing prospective multicentre epidemiological study in the USA [9].…”

Section: To the Editorsmentioning

confidence: 97%

Sitaxentan-related acute liver failure in a patient with pulmonary arterial hypertension

Lee¹,

Kirkham²,

Johnson³

et al. 2011

European Respiratory Journal

View full text Add to dashboard Cite

“…One case was a cholestatic type, another one was hepatocellular and the last two were drug-induced acute autoimmune hepatitis. Our patient presented as serious hepatocellular hepatitis [9] . Patients with acute toxic hepatocellular damage are at high risk of acute liver failure.…”

Section: Introductionmentioning

confidence: 72%

Serious drug-induced liver disease secondary to ezetimibe

Castellote¹,

Ariza²,

Rota³

et al. 2008

WJG

View full text Add to dashboard Cite

Risk of acute liver injury associated with the use of drugs: a multicentre population survey

Abstract: SUMMARY BackgroundAcute liver injury of uncertain aetiology is often drug related and quantitative information about the associated risk is scarce.

Cited by 60 publications

References 28 publications

Phase I Trial of Erlotinib Combined with Cisplatin and Radiotherapy for Patients with Locally Advanced Cervical Squamous Cell Cancer

Phase I Trial of Erlotinib Combined with Cisplatin and Radiotherapy for Patients with Locally Advanced Cervical Squamous Cell Cancer

Sitaxentan-related acute liver failure in a patient with pulmonary arterial hypertension

Serious drug-induced liver disease secondary to ezetimibe

Contact Info

Product

Resources

About